Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting the genomic science, reimbursement discussions, and clinical-trial data buried inside GeneDx’s SEC disclosures can feel like decoding DNA itself. From recognizing revenue tied to whole-genome tests to tracking how rapid NICU sequencing affects margins, the company’s reports are dense with technical language. That’s why investors searching for “GeneDx SEC filings explained simply” start here.
Stock Titan’s platform turns those complexities into clarity. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, and 8-K material events the moment they hit EDGAR, then serves up concise highlights. Need the “GeneDx annual report 10-K simplified” to see year-over-year R&D spending? Done. Curious about clinical-trial milestones disclosed in an 8-K? They’re distilled in seconds—“GeneDx 8-K material events explained.” Real-time alerts flag each “GeneDx Form 4 insider transactions real-time,” letting you monitor “GeneDx executive stock transactions Form 4” without combing filings. Our summaries also connect reimbursement risk factors to revenue trends, so “GeneDx earnings report filing analysis” becomes a quick read instead of a weekend project.
Every filing type unlocks a different lens on this precision-medicine pioneer: the “GeneDx quarterly earnings report 10-Q filing” reveals test-volume growth; the “GeneDx proxy statement executive compensation” shows how leadership is incentivized to expand the rare-disease dataset; “GeneDx insider trading Form 4 transactions” expose buying or selling before pivotal FDA updates. With AI-powered summaries, expert context, and real-time coverage of all forms, understanding GeneDx’s path—from lab bench to bedside—is finally straightforward. Investors use these insights to spot emerging reimbursement trends, evaluate cash burn, and benchmark genomic-data assets—all without wading through hundreds of pages. For anyone “understanding GeneDx SEC documents with AI,” this is the single page to bookmark.
Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.
The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.
Form 144 notice for GeneDx Holdings Corp. (symbol WGS) documents a proposed sale of 500,000 shares of Class A common stock through Jefferies LLC, with an aggregate market value of $60,451,950 and an approximate sale date of 08/22/2025 on NASDAQ. The filing states the shares were purchased from the issuer on 01/27/2023 for cash. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer. The filing does not name the selling person or provide additional context about ownership or intent.
Casdin-related parties reported insider sales of GeneDx Holdings Corp. (WGS) common stock on 08/22/2025. The filing shows a sale of 500,000 shares of Class A common stock at $120.9039 per share. After the reported transactions, the group reports beneficial ownership of 3,007,164 shares on an indirect basis. The Form 4 lists additional holdings and dispositions across related entities and individuals, including direct ownership of 20,518 shares and indirect positions of 19,247 and 333,144 shares, with explanatory footnotes describing relationships among Casdin Capital, Casdin Partners funds, the GP and Eli Casdin.
Summit Partners and affiliated entities reported beneficial ownership of 867,265 shares of GeneDx Holdings Corp. Class A common stock, representing 3.04% of the outstanding shares based on 28,553,204 common shares used for the calculation. The holdings are aggregated across several funds and accounts managed by Summit Partners Public Asset Management (SPPAM), with Summit Partners, L.P. serving as the managing member.
The filing shows the group has 0 sole voting power, 771,333 shares subject to shared voting power and 867,265 shares subject to shared dispositive power. SPPAM is identified as the investment manager for the funds holding the positions. The reporting persons state the securities were not acquired to influence control and the filing is made under a joint filing agreement with powers of attorney for certain signatories.
GeneDx Holdings (WGS) – Amended Form 4 (filed 08-07-25)
Director and 10 % owner Eli Casdin reported the vesting and immediate settlement of 12,924 RSUs on 06-18-25, converting to Class A common shares at $0 exercise cost. Following the event, Casdin now holds 20,518 shares directly and, through various affiliated entities, 3.86 million shares indirectly (3,507,164 via Casdin Partners Master Fund LP, 333,144 via CMLS Holdings LLC, and 19,247 via Casdin Partners GP LLC).
The amendment corrects prior clerical errors: earlier filings over-stated direct holdings by 1,376 shares and under-stated them by 4,452 shares in separate periods. No open-market purchases or sales occurred; transactions solely reflect RSU vesting. The RSUs will continue to vest on the earlier of the next annual meeting or one-year anniversary, contingent on service.
Investor takeaway: The filing increases disclosure accuracy but does not involve cash transactions or alter the overall economic exposure of this significant insider.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
